Lawmakers Probe Easing Pot Research's Regulatory Gridlock

Law360 (January 15, 2020, 5:22 PM EST) -- During a House subcommittee hearing on cannabis policy Wednesday, lawmakers barely discussed any of the marijuana reform bills on the agenda, instead using much of the time to grill witnesses from federal agencies on what they could do to expedite further marijuana research with their existing powers.

The recurring theme of the 3½-hour session was the catch-22 created by the Controlled Substances Act, which designated cannabis a Schedule I substance with no accepted medical use and erected a host of regulatory obstacles to those attempting to research it.

This has led to a scarcity of data on marijuana's risks and benefits,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS